WUXI BIO (02269): Miao Jingwen appointed as non-executive director.
Wu Yibing, Ph.D., has resigned as of November 20, 2024, in an announcement from WuXi Biologics (02269).
WUXI BIO (02269) announces that, effective from November 20, 2024, Dr. Wu Yibing has resigned as a non-executive director and member of the Board's decision-making committee to dedicate more time to other personal matters. Ms. Miao Jingwen has been appointed as a non-executive director and member of the decision-making committee.
Related Articles
Microsoft Corporation (MSFT.US) Azure takes the lead and becomes the first global cloud service provider to begin validating the NVIDIA Corporation Vera Rubin NVL72 system.
HK Bull/Bear Outstanding Qty Ratio(60:40) | March 14th
The seven giants of the US stock market have all entered a technical correction zone. Microsoft Corporation (MSFT.US) has fallen by more than 18% since the beginning of this year.
Microsoft Corporation (MSFT.US) Azure takes the lead and becomes the first global cloud service provider to begin validating the NVIDIA Corporation Vera Rubin NVL72 system.
HK Bull/Bear Outstanding Qty Ratio(60:40) | March 14th
The seven giants of the US stock market have all entered a technical correction zone. Microsoft Corporation (MSFT.US) has fallen by more than 18% since the beginning of this year.
RECOMMEND
“A+H” Team Continues To Expand Hard Technology Firms Accelerate Global Deployment
11/03/2026
Anti‑Stagflation Theme Guides Hong Kong Allocation Institutions Identify Power And Energy Assets As Short‑Term Core
11/03/2026
U.S. Equities Enter “Always‑On” Trading Era Nasdaq Advances Stock Tokenization Framework
11/03/2026
